Mounjaro 7.5mg/Week Dose Formulation Availability
Yes, there is absolutely a 7.5mg/week dose formulation of Mounjaro (tirzepatide) available. This is a standard FDA-approved dose strength in the tirzepatide titration schedule.
FDA-Approved Dose Strengths
Mounjaro is available in six distinct dose strengths, all administered as once-weekly subcutaneous injections 1:
- 2.5 mg/0.5 mL - Starting dose for treatment initiation (not intended for glycemic control) 1
- 5 mg/0.5 mL - First therapeutic dose after 4 weeks 1
- 7.5 mg/0.5 mL - Available for dose escalation 1
- 10 mg/0.5 mL - Available for dose escalation 1
- 12.5 mg/0.5 mL - Available for dose escalation 1
- 15 mg/0.5 mL - Maximum approved dose 1
Standard Titration Schedule
The FDA-approved titration protocol explicitly includes the 7.5mg dose as part of the standard escalation pathway 1:
- Weeks 1-4: Start at 2.5 mg once weekly 1
- After 4 weeks: Increase to 5 mg once weekly 1
- Subsequent escalation: If additional glycemic control is needed, increase the dose in 2.5 mg increments after at least 4 weeks on the current dose 1
- This means the progression would be: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg 1
Available Formulations
The 7.5mg dose is available in two formulation types 1:
- Pre-filled single-dose pens: 4 pens per carton, each containing 7.5 mg/0.5 mL 1
- Single-dose vials: Individual vials containing 7.5 mg/0.5 mL (needles and syringes not included) 1
Clinical Context for Your Patient
For a patient with type 2 diabetes who has been on 5mg/week for at least 4 weeks 1:
- The 7.5mg dose is the appropriate next step if additional glycemic control is needed 1
- The dose escalation should occur after at least 4 weeks on the current 5mg dose 1
- This gradual titration reduces the risk of gastrointestinal adverse reactions 1
- The patient can continue escalating in 2.5mg increments every 4 weeks up to the maximum dose of 15mg weekly if needed 1
Common Pitfall to Avoid
Do not confuse the 2.5mg starting dose (which is for treatment initiation only and not intended for glycemic control) with the absence of intermediate dose strengths 1. All six dose strengths from 2.5mg through 15mg are FDA-approved and commercially available 1.